Your browser doesn't support javascript.
loading
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
Traylor, Matthew; Persyn, Elodie; Tomppo, Liisa; Klasson, Sofia; Abedi, Vida; Bakker, Mark K; Torres, Nuria; Li, Linxin; Bell, Steven; Rutten-Jacobs, Loes; Tozer, Daniel J; Griessenauer, Christoph J; Zhang, Yanfei; Pedersen, Annie; Sharma, Pankaj; Jimenez-Conde, Jordi; Rundek, Tatjana; Grewal, Raji P; Lindgren, Arne; Meschia, James F; Salomaa, Veikko; Havulinna, Aki; Kourkoulis, Christina; Crawford, Katherine; Marini, Sandro; Mitchell, Braxton D; Kittner, Steven J; Rosand, Jonathan; Dichgans, Martin; Jern, Christina; Strbian, Daniel; Fernandez-Cadenas, Israel; Zand, Ramin; Ruigrok, Ynte; Rost, Natalia; Lemmens, Robin; Rothwell, Peter M; Anderson, Christopher D; Wardlaw, Joanna; Lewis, Cathryn M; Markus, Hugh S.
Afiliação
  • Traylor M; Clinical Pharmacology and The Barts Heart Centre and NIHR Barts Biomedical Research Centre, Barts Health NHS Trust, William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Persyn E; Department of Medical and Molecular Genetics, King's College London, London, UK.
  • Tomppo L; Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
  • Klasson S; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Abedi V; Department of Molecular and Functional Genomics, Weis Center for Research, Geisinger Health System, Danville, PA, USA.
  • Bakker MK; Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands.
  • Torres N; Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Li L; Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.
  • Bell S; Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Rutten-Jacobs L; Product Development Personalized Health Care, F Hoffmann-La Roche, Basel, Switzerland.
  • Tozer DJ; Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Griessenauer CJ; Neuroscience Institute, Geisinger Health System, Danville, PA, USA; Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria.
  • Zhang Y; Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA.
  • Pedersen A; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Sharma P; Institute of Cardiovascular Research, Royal Holloway University of London, London, UK.
  • Jimenez-Conde J; Neurovascular Research Group, Department of Neurology of Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mediques), Universitat Autonoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain.
  • Rundek T; Evelyn F McKnight Brain Institute, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Grewal RP; Neuroscience Institute, Saint Francis Medical Center, School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, USA.
  • Lindgren A; Department of Neurology, Skane University Hospital, Lund, Sweden; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden.
  • Meschia JF; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Salomaa V; Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Havulinna A; Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM HiLIFE), Helsinki, Finland.
  • Kourkoulis C; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Crawford K; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Marini S; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Mitchell BD; Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA.
  • Kittner SJ; Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA; Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA.
  • Rosand J; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Br
  • Dichgans M; Institute for Stroke and Dementia Research (ISD), LMU Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Jern C; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Strbian D; Department of Neurology, Helsinki University Hospital, Helsinki, Finland; Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
  • Fernandez-Cadenas I; Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; Neurovascular Research Laboratory and Neurovascular Unit, Institut de Recerca, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Zand R; Neuroscience Institute, Geisinger Health System, Danville, PA, USA.
  • Ruigrok Y; Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands.
  • Rost N; J Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA.
  • Lemmens R; Experimental Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; VIB Center for Brain & Disease Research, Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Rothwell PM; Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.
  • Anderson CD; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Br
  • Wardlaw J; Centre for Clinical Brain Sciences, UK Dementia Research Institute and Row Fogo Centre for Research into the Ageing Brain, University of Edinburgh, Edinburgh, UK.
  • Lewis CM; Department of Medical and Molecular Genetics, King's College London, London, UK; Social, Genetic, and Developmental Psychiatry Centre, King's College London, London, UK.
  • Markus HS; Clinical Neurosciences, University of Cambridge, Cambridge, UK. Electronic address: hsm32@medschl.cam.ac.uk.
Lancet Neurol ; 20(5): 351-361, 2021 05.
Article em En | MEDLINE | ID: mdl-33773637
ABSTRACT

BACKGROUND:

The genetic basis of lacunar stroke is poorly understood, with a single locus on 16q24 identified to date. We sought to identify novel associations and provide mechanistic insights into the disease.

METHODS:

We did a pooled analysis of data from newly recruited patients with an MRI-confirmed diagnosis of lacunar stroke and existing genome-wide association studies (GWAS). Patients were recruited from hospitals in the UK as part of the UK DNA Lacunar Stroke studies 1 and 2 and from collaborators within the International Stroke Genetics Consortium. Cases and controls were stratified by ancestry and two meta-analyses were done a European ancestry analysis, and a transethnic analysis that included all ancestry groups. We also did a multi-trait analysis of GWAS, in a joint analysis with a study of cerebral white matter hyperintensities (an aetiologically related radiological trait), to find additional genetic associations. We did a transcriptome-wide association study (TWAS) to detect genes for which expression is associated with lacunar stroke; identified significantly enriched pathways using multi-marker analysis of genomic annotation; and evaluated cardiovascular risk factors causally associated with the disease using mendelian randomisation.

FINDINGS:

Our meta-analysis comprised studies from Europe, the USA, and Australia, including 7338 cases and 254 798 controls, of which 2987 cases (matched with 29 540 controls) were confirmed using MRI. Five loci (ICA1L-WDR12-CARF-NBEAL1, ULK4, SPI1-SLC39A13-PSMC3-RAPSN, ZCCHC14, ZBTB14-EPB41L3) were found to be associated with lacunar stroke in the European or transethnic meta-analyses. A further seven loci (SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, FOXF2-FOXQ1, VTA1-GPR126, SH3PXD2A, HTRA1-ARMS2, COL4A2) were found to be associated in the multi-trait analysis with cerebral white matter hyperintensities (n=42 310). Two of the identified loci contain genes (COL4A2 and HTRA1) that are involved in monogenic lacunar stroke. The TWAS identified associations between the expression of six genes (SCL25A44, ULK4, CARF, FAM117B, ICA1L, NBEAL1) and lacunar stroke. Pathway analyses implicated disruption of the extracellular matrix, phosphatidylinositol 5 phosphate binding, and roundabout binding (false discovery rate <0·05). Mendelian randomisation analyses identified positive associations of elevated blood pressure, history of smoking, and type 2 diabetes with lacunar stroke.

INTERPRETATION:

Lacunar stroke has a substantial heritable component, with 12 loci now identified that could represent future treatment targets. These loci provide insights into lacunar stroke pathogenesis, highlighting disruption of the vascular extracellular matrix (COL4A2, LOX, SH3PXD2A, GPR126, HTRA1), pericyte differentiation (FOXF2, GPR126), TGF-ß signalling (HTRA1), and myelination (ULK4, GPR126) in disease risk.

FUNDING:

British Heart Foundation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Acidente Vascular Cerebral Lacunar Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Lancet Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Acidente Vascular Cerebral Lacunar Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Lancet Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido